Showing results (31-40 of 225) with videos related to

Sort By:
Pageof 23
Journal of Acquired Immune Deficiency Syndromes (1999)|February 7, 2003
Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant womenSalome N Juethner, Catherine Williamson, Maria B Ristig, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 28, 2007
Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitroXu Wang, Steven D Douglas, Jian-Ping Lai, et al.
AIDS Care|November 24, 2011
Impact of transitioning from HIV clinical trials to routine medical care on clinical outcomes and patient perceptionsBaligh R Yehia, Judith A Long, Cordelia R Stearns, et al.
AIDS (London, England)|February 25, 2003
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin DMario Cozzolino, Marcos Vidal, Maria Vittoria Arcidiacono, et al.
Nucleic Acids Research|June 20, 2007
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutationsChristian Hoffmann, Nana Minkah, Jeremy Leipzig, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2006
Management of potential neurocysticercosis in patients with HIV infectionSashank Prasad, Rob Roy MacGregor, Pablo Tebas, et al.
Open Forum Infectious Diseases|March 15, 2024
Combination of Extended Antivirals With Antiretrovirals for Severe Mpox in Advanced Human Immunodeficiency Virus Infection: Case Series of 4 PatientsMichael T Duong, Pablo Tebas, Bhavya Ancha, et al.
Archives of Medical Research|July 23, 2013
In vitro and in vivo effects of IGF-I on adiposity in HIV-associated metabolic disease: a pilot studyRoy J Kim, Sumit Vaghani, Larisa M Zifchak, et al.
AIDS and Behavior|August 20, 2010
Risk factors for medication non-adherence in an HIV infected population in the Dominican RepublicJulian Harris, Mara Pillinger, Deborah Fromstein, et al.
AIDS Research and Human Retroviruses|July 10, 2004
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infectionPablo Tebas, Kevin Yarasheski, Keith Henry, et al.
Pageof 23